Assembly Biosciences (ASMB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.20
- Estimate
- -$0.52
- Surprise
- +61.9%
- Revenue (period 2026-06-30)
- $13.4M
- Score today
- 6.3/10
Revenue source: xbrl.
How the report landed
Assembly Biosciences (ASMB) reported a narrower loss than forecast — diluted EPS of -$0.20 against the -$0.52 estimate (a 61.9% beat on a still-unprofitable quarter).
Coverage in the report window
- Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates ASMB Sell at 6.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +61.9% surprise compares with a +114.9% four-quarter average.
What argues against it
- Quality below floor (1.7 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -0.9%), High leverage (D/E 52.4)
- Momentum score 3.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $29.80
- Price target
- $45.24
- Stop
- $28.79
- Upside to target
- +51.8%
- Reward-to-risk
- 4.3:1
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
ASMB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $606.7M
- P/E (fwd)
- -11.6
- P/E (ttm)
- 24.0
- 52-week range
- $20.23–$39.71
- Off 52-week high
- 25.0%
- RSI (14)
- 33
- Volume vs avg
- 0.79×
- Score today
- 6.3/10